tooluniverse-drug-regulatory
Compare original and translation side by side
🇺🇸
Original
English🇨🇳
Translation
ChineseDrug Regulatory Research
药品监管研究
Regulatory status depends on jurisdiction. FDA approval does not equal EMA approval — check the specific market the user is asking about. Generic availability depends on BOTH patent expiry AND regulatory approval — a patent may have expired but no ANDA may yet be filed or approved. Exclusivity codes (NCE, ODE, PED) can block generics even after patent expiry; always check before concluding a generic can enter. A 505(b)(2) NDA is not a generic — it requires its own clinical data and gets its own exclusivity period.
FDA_OrangeBook_get_exclusivityLOOK UP DON'T GUESS: never assume NDA numbers, exclusivity dates, or ATC codes — always call FDAGSRS, Orange Book, and RxClass tools to retrieve current data; regulatory status changes with new approvals and expirations.
Regulatory intelligence for drugs: identify FDA substances, classify drugs by therapeutic
category, check approval and generic status, retrieve label sections, and find clinical trials.
监管状态取决于管辖区域。FDA批准并不等同于EMA批准——请确认用户询问的具体市场。仿制药的可用性取决于专利到期和监管批准两者——专利可能已到期,但仿制药申请(ANDA)可能尚未提交或获批。即使专利到期,独占性代码(NCE、ODE、PED)仍可能阻止仿制药进入;在得出仿制药可进入市场的结论前,务必先调用工具。505(b)(2) NDA并非仿制药——它需要自身的临床数据,并拥有独立的独占期。
FDA_OrangeBook_get_exclusivity务必查询而非猜测:切勿假设NDA编号、独占性日期或ATC代码——务必调用FDAGSRS、橙皮书和RxClass工具获取最新数据;监管状态会随新批准和到期情况发生变化。
药品监管情报:识别FDA注册物质、按治疗类别对药品进行分类、查询批准与仿制药状态、提取标签内容、查找临床试验。
When to Use
适用场景
- "What is the FDA regulatory status of semaglutide?"
- "Is there a generic for Humira?"
- "What ATC class does metformin belong to?"
- "Get adverse reactions from the ibuprofen drug label"
- "When does the patent for Eliquis expire?"
- "List all drugs in the ACE inhibitor class"
- "Find clinical trials for a biosimilar of adalimumab"
- "司美格鲁肽的FDA监管状态是什么?"
- "修美乐有仿制药吗?"
- "二甲双胍属于哪个ATC类别?"
- "获取布洛芬药品标签中的不良反应信息"
- "阿哌沙班的专利何时到期?"
- "列出所有ACE抑制剂类药品"
- "查找阿达木单抗生物类似药的临床试验"
NOT for (use other skills instead)
不适用场景(请使用其他工具)
- Drug-drug interactions -> Use
tooluniverse-drug-drug-interaction - Pharmacogenomics / dosing by genotype -> Use
tooluniverse-pharmacogenomics - Drug mechanism of action / target binding -> Use
tooluniverse-drug-mechanism-research - Drug repurposing / new indications -> Use
tooluniverse-drug-repurposing
- 药物相互作用 -> 使用
tooluniverse-drug-drug-interaction - 药物基因组学 / 基于基因型的给药方案 -> 使用
tooluniverse-pharmacogenomics - 药物作用机制 / 靶点结合 -> 使用
tooluniverse-drug-mechanism-research - 药物重定位 / 新适应症 -> 使用
tooluniverse-drug-repurposing
Workflow Overview
工作流概述
Input (drug name / brand name / UNII)
|
v
Phase 1: Substance Identification -- FDAGSRS_search_substances, FDAGSRS_get_substance
|
v
Phase 2: Drug Classification -- RxClass_get_drug_classes, RxClass_find_classes
|
v
Phase 3: Approval & Generic Status -- FDA_OrangeBook_search_drug, FDA_OrangeBook_check_generic_availability
|
v
Phase 4: Patent & Exclusivity -- FDA_OrangeBook_get_patent_info, FDA_OrangeBook_get_exclusivity
|
v
Phase 5: Label Parsing -- DailyMed_parse_adverse_reactions, DailyMed_parse_dosing, etc.
|
v
Phase 6: Clinical Trials -- search_clinical_trials
|
v
Phase 7: Pharmacovigilance -- FAERS_count_reactions_by_drug_event (param: medicinalproduct)
|
v
Phase 8: Literature & Approval -- PubMed_search_articles, OpenFDA_get_approval_history, RxNorm_get_drug_namesSupplementary tools (not in core phases but useful):
— full FDA submission/approval history (requiresOpenFDA_get_approval_historyparam)operation — top adverse events by report count (param:FAERS_count_reactions_by_drug_event, ALL CAPS)medicinalproduct — resolve drug to RXCUI and brand namesRxNorm_get_drug_names — DrugBank ID, CAS, UNII lookupdrugbank_vocab_search — regulatory and clinical literaturePubMed_search_articles
输入(药品名称 / 品牌名 / UNII)
|
v
阶段1:物质识别 -- FDAGSRS_search_substances, FDAGSRS_get_substance
|
v
阶段2:药品分类 -- RxClass_get_drug_classes, RxClass_find_classes
|
v
阶段3:批准与仿制药状态 -- FDA_OrangeBook_search_drug, FDA_OrangeBook_check_generic_availability
|
v
阶段4:专利与独占性 -- FDA_OrangeBook_get_patent_info, FDA_OrangeBook_get_exclusivity
|
v
阶段5:标签解析 -- DailyMed_parse_adverse_reactions, DailyMed_parse_dosing, etc.
|
v
阶段6:临床试验 -- search_clinical_trials
|
v
阶段7:药物警戒 -- FAERS_count_reactions_by_drug_event (参数: medicinalproduct)
|
v
阶段8:文献与审批 -- PubMed_search_articles, OpenFDA_get_approval_history, RxNorm_get_drug_names补充工具(不属于核心阶段但实用):
— 完整的FDA提交/审批历史(需OpenFDA_get_approval_history参数)operation — 按报告数量排序的主要不良事件(参数:FAERS_count_reactions_by_drug_event,需全部大写)medicinalproduct — 将药品解析为RXCUI和品牌名RxNorm_get_drug_names — DrugBank ID、CAS、UNII查询drugbank_vocab_search — 监管与临床文献PubMed_search_articles
Phase 1: Substance Identification (FDAGSRS)
阶段1:物质识别(FDAGSRS)
FDAGSRS_search_substances: (string REQUIRED -- drug name, UNII, InChIKey, or formula), (string, optional: "chemical"/"protein"/"nucleic acid"/"polymer"/"mixture"), (int, 1-50, default 10).
Returns .
querysubstance_classlimit{status, data: {substances: [{unii, name, substance_class, status, cross_references: [{type, value}]}]}}- contains DrugBank IDs, WHO-ATC codes, CAS numbers, CFR citations.
cross_references - Use to get the official UNII identifier before calling .
FDAGSRS_get_substance
FDAGSRS_get_substance: (string REQUIRED, 10-char FDA UNII code).
Returns complete substance record including all synonyms, names, structure, and cross-references.
unii- Provides definitive list of all registered names (INN, USAN, brand, chemical).
FDAGSRS_get_structure: (string REQUIRED).
Returns .
unii{status, data: {smiles, formula, inchikey, molfile, molecular_weight, stereochemistry, optical_activity}}- Only works for chemical substances; returns error for biologics, mixtures, polymers.
python
undefinedFDAGSRS_search_substances:(必填字符串——药品名称、UNII、InChIKey或分子式),(可选字符串:"chemical"/"protein"/"nucleic acid"/"polymer"/"mixture"),(整数,1-50,默认10)。
返回。
querysubstance_classlimit{status, data: {substances: [{unii, name, substance_class, status, cross_references: [{type, value}]}]}}- 包含DrugBank ID、WHO-ATC代码、CAS编号、CFR引用。
cross_references - 调用前,需通过此工具获取官方UNII标识符。
FDAGSRS_get_substance
FDAGSRS_get_substance:(必填字符串,10位FDA UNII代码)。
返回完整的物质记录,包括所有同义词、名称、结构和交叉引用。
unii- 提供所有注册名称的权威列表(INN、USAN、品牌名、化学名)。
FDAGSRS_get_structure:(必填字符串)。
返回。
unii{status, data: {smiles, formula, inchikey, molfile, molecular_weight, stereochemistry, optical_activity}}- 仅适用于化学物质;若为生物制品、混合物或聚合物,将返回错误。
python
undefinedFull substance lookup workflow
完整物质查询工作流
search = tu.tools.FDAGSRS_search_substances(query="semaglutide")
unii = search["data"]["substances"][0]["unii"]
full = tu.tools.FDAGSRS_get_substance(unii=unii)
---search = tu.tools.FDAGSRS_search_substances(query="semaglutide")
unii = search["data"]["substances"][0]["unii"]
full = tu.tools.FDAGSRS_get_substance(unii=unii)
---Phase 2: Drug Classification (RxClass)
阶段2:药品分类(RxClass)
RxClass_get_drug_classes: (string, drug name), (string, RxNorm RXCUI -- alternative to drug_name), (string, optional: "ATC"/"FDASPL"/"MESH"/"VA"), (int, default 20).
Returns .
drug_namerxcuirela_sourcelimit{status, data: {classes: [{class_id, class_name, class_type, rela}]}}- Returns ALL classification systems unless filters to one.
rela_source - values: "ATC1-4", "EPC" (FDA Established Pharmacologic Class), "MoA", "VA", "MESH".
class_type - Use to find a drug's ATC code, pharmacological class, mechanism of action label.
RxClass_find_classes: (string REQUIRED, keyword e.g., "beta blocker"), (string, optional: "ATC1-4"/"EPC"/"MoA"), (int, default 20).
Returns matching drug classes with class IDs.
queryclass_typelimit- Use when you need to find a class ID before calling .
RxClass_get_class_members
RxClass_get_class_members: (string REQUIRED, e.g., "M01AE"), (string, optional: "ATC"/"FDASPL"), (string, optional: "IN" for ingredients), (int, default 50).
Returns all drug ingredients in the class with RXCUIs and names.
class_idrela_sourcettyslimit- restricts to active ingredient-level entries (recommended).
ttys="IN"
python
undefinedRxClass_get_drug_classes:(字符串,药品名称),(字符串,RxNorm RXCUI——替代drug_name的参数),(可选字符串:"ATC"/"FDASPL"/"MESH"/"VA"),(整数,默认20)。
返回。
drug_namerxcuirela_sourcelimit{status, data: {classes: [{class_id, class_name, class_type, rela}]}}- 除非通过筛选,否则会返回所有分类系统的结果。
rela_source - 取值:"ATC1-4"、"EPC"(FDA确立药理学分类)、"MoA"、"VA"、"MESH"。
class_type - 用于查找药品的ATC代码、药理学分类、作用机制标签。
RxClass_find_classes:(必填字符串,关键词如"beta blocker"),(可选字符串:"ATC1-4"/"EPC"/"MoA"),(整数,默认20)。
返回匹配的药品类别及类别ID。
queryclass_typelimit- 当需要先获取类别ID再调用时使用。
RxClass_get_class_members
RxClass_get_class_members:(必填字符串,如"M01AE"),(可选字符串:"ATC"/"FDASPL"),(可选字符串:"IN"表示活性成分),(整数,默认50)。
返回该类别下所有药品活性成分的RXCUIs和名称。
class_idrela_sourcettyslimit- 推荐传入以限制结果为活性成分层级的条目。
ttys="IN"
python
undefinedFind all proton pump inhibitors
查找所有质子泵抑制剂
classes = tu.tools.RxClass_find_classes(query="proton pump inhibitor", class_type="EPC")
class_id = classes["data"]["classes"][0]["class_id"]
members = tu.tools.RxClass_get_class_members(class_id=class_id, ttys="IN")
---classes = tu.tools.RxClass_find_classes(query="proton pump inhibitor", class_type="EPC")
class_id = classes["data"]["classes"][0]["class_id"]
members = tu.tools.RxClass_get_class_members(class_id=class_id, ttys="IN")
---Phase 3: Approval & Generic Status (FDA Orange Book)
阶段3:批准与仿制药状态(FDA橙皮书)
FDA_OrangeBook_search_drug: (string), (string), (string), (int, default 10).
Returns .
brand_namegeneric_nameapplication_numberlimit{status, data: {products: [{brand_name, generic_name, dosage_form, strength, te_code, application_number, approval_date}]}}- Use brand name (UPPERCASE) or generic name to find NDA/ANDA numbers and approval info.
- : Therapeutic Equivalence code (e.g., "AB" = therapeutically equivalent).
te_code
FDA_OrangeBook_check_generic_availability: (string), (string).
Returns .
brand_namegeneric_name{status, data: {reference_listed_drug, generics_available: bool, generics_count, generic_products: [...]}}- Primary tool for "is there a generic?" questions.
FDA_OrangeBook_get_te_code: No special params beyond /.
Returns therapeutic equivalence codes for substitutability assessment.
brand_nameapplication_numberFDA_OrangeBook_get_approval_history: (string, e.g., "NDA020402").
Returns chronological approval history including supplemental approvals and label changes.
application_numberpython
undefinedFDA_OrangeBook_search_drug:(字符串),(字符串),(字符串),(整数,默认10)。
返回。
brand_namegeneric_nameapplication_numberlimit{status, data: {products: [{brand_name, generic_name, dosage_form, strength, te_code, application_number, approval_date}]}}- 使用品牌名(大写)或通用名查找NDA/ANDA编号及审批信息。
- :治疗等效性代码(如"AB"=治疗等效)。
te_code
FDA_OrangeBook_check_generic_availability:(字符串),(字符串)。
返回。
brand_namegeneric_name{status, data: {reference_listed_drug, generics_available: bool, generics_count, generic_products: [...]}}- 是回答“是否有仿制药?”问题的核心工具。
FDA_OrangeBook_get_te_code:除/外无特殊参数。
返回用于可替代性评估的治疗等效性代码。
brand_nameapplication_numberFDA_OrangeBook_get_approval_history:(字符串,如"NDA020402")。
返回按时间排序的审批历史,包括补充审批和标签变更。
application_numberpython
undefinedCheck generic availability
查询仿制药可用性
result = tu.tools.FDA_OrangeBook_check_generic_availability(brand_name="LIPITOR")
result = tu.tools.FDA_OrangeBook_check_generic_availability(brand_name="LIPITOR")
result["data"]["generics_available"] -> True
result["data"]["generics_available"] -> True
result["data"]["generics_count"] -> N
result["data"]["generics_count"] -> N
---
---Phase 4: Patent & Exclusivity
阶段4:专利与独占性
FDA_OrangeBook_get_patent_info: (string), (string).
Returns patent information. Note: Full patent numbers and expiration dates require Orange Book data files.
application_numberbrand_nameFDA_OrangeBook_get_exclusivity: (string), (string).
Returns .
application_numberbrand_name{status, data: {exclusivities: [{exclusivity_code, exclusivity_date, description}]}}- values: "NCE" (New Chemical Entity, 5 years), "ODE" (Orphan Drug, 7 years), "PED" (Pediatric, 6 months), "NP" (New Product), "M" (new formulation).
exclusivity_code
FDA_OrangeBook_get_patent_info:(字符串),(字符串)。
返回专利信息。注意:完整专利编号和到期日期需要橙皮书数据文件支持。
application_numberbrand_nameFDA_OrangeBook_get_exclusivity:(字符串),(字符串)。
返回。
application_numberbrand_name{status, data: {exclusivities: [{exclusivity_code, exclusivity_date, description}]}}- 取值:"NCE"(新化学实体,5年)、"ODE"(孤儿药,7年)、"PED"(儿科用药,6个月)、"NP"(新产品)、"M"(新剂型)。
exclusivity_code
Phase 5: Label Parsing (DailyMed)
阶段5:标签解析(DailyMed)
All DailyMed parse tools accept either (SPL Set ID UUID) OR (auto-lookup).
Using is recommended when the setid is unknown.
setiddrug_namedrug_nameDailyMed_parse_adverse_reactions: or . Returns structured adverse reaction table with frequencies and severity.
setiddrug_nameDailyMed_parse_dosing: or . Returns dosage and administration section (doses, schedules, renal/hepatic adjustments).
setiddrug_nameDailyMed_parse_contraindications: or . Returns contraindications section.
setiddrug_nameDailyMed_parse_drug_interactions: or . Returns drug-drug interaction section with clinical management guidance.
setiddrug_nameDailyMed_parse_clinical_pharmacology: or . Returns PK/PD data (Cmax, AUC, half-life, protein binding, metabolism pathway).
setiddrug_nameDailyMed_search_spls: (string), returns SPL Set IDs for that drug. Use to find when needed explicitly.
drug_namesetidpython
undefined所有DailyMed解析工具均接受(SPL Set ID UUID)或(自动查询)作为参数。
当未知setid时,推荐使用。
setiddrug_namedrug_nameDailyMed_parse_adverse_reactions:或。返回结构化的不良反应表格,包含发生率和严重程度。
setiddrug_nameDailyMed_parse_dosing:或。返回给药方案章节(剂量、给药频次、肾/肝功能调整)。
setiddrug_nameDailyMed_parse_contraindications:或。返回禁忌症章节。
setiddrug_nameDailyMed_parse_drug_interactions:或。返回药物相互作用章节及临床管理指导。
setiddrug_nameDailyMed_parse_clinical_pharmacology:或。返回药代/药效数据(Cmax、AUC、半衰期、蛋白结合率、代谢途径)。
setiddrug_nameDailyMed_search_spls:(字符串),返回该药品的SPL Set ID。当需要明确使用setid时调用。
drug_namepython
undefinedParse adverse reactions for apixaban
解析阿哌沙班的不良反应
ae = tu.tools.DailyMed_parse_adverse_reactions(drug_name="apixaban")
---ae = tu.tools.DailyMed_parse_adverse_reactions(drug_name="apixaban")
---Phase 6: Clinical Trials
阶段6:临床试验
search_clinical_trials: (string), (string), (string), (int, alias: /), (array, alias: ).
Returns .
conditioninterventionquery_termpageSizemax_resultslimitoverall_statusstatus{status, data: {studies: [{NCT ID, brief_title, brief_summary, overall_status, phase}], total_count}}- Use for drug name,
interventionfor disease.condition - Filter for active enrollment.
overall_status=["RECRUITING"] - may be None even when results exist; check
total_count.len(studies) > 0
python
undefinedsearch_clinical_trials:(字符串),(字符串),(字符串),(整数,别名:/),(数组,别名:)。
返回。
conditioninterventionquery_termpageSizemax_resultslimitoverall_statusstatus{status, data: {studies: [{NCT ID, brief_title, brief_summary, overall_status, phase}], total_count}}- 使用传入药品名称,
intervention传入疾病名称。condition - 通过筛选正在招募的试验。
overall_status=["RECRUITING"] - 即使存在结果,也可能为None;需检查
total_count。len(studies) > 0
python
undefinedFind recruiting trials for a biosimilar
查找正在招募的阿达木单抗生物类似药临床试验
trials = tu.tools.search_clinical_trials(
intervention="adalimumab biosimilar",
overall_status=["RECRUITING"],
pageSize=10
)
---trials = tu.tools.search_clinical_trials(
intervention="adalimumab biosimilar",
overall_status=["RECRUITING"],
pageSize=10
)
---Example Workflows
示例工作流
Workflow 1: Full Regulatory Profile for a Drug
工作流1:药品完整监管档案
1. FDAGSRS_search_substances(query="apixaban")
-> UNII, substance class, ATC/DrugBank cross-refs
2. RxClass_get_drug_classes(drug_name="apixaban", rela_source="ATC")
-> ATC code B01AF02 (direct factor Xa inhibitor)
3. FDA_OrangeBook_search_drug(brand_name="ELIQUIS")
-> NDA206518, approval date, TE code
4. FDA_OrangeBook_check_generic_availability(brand_name="ELIQUIS")
-> Generic availability status
5. FDA_OrangeBook_get_exclusivity(brand_name="ELIQUIS")
-> Exclusivity codes and expiration dates
6. DailyMed_parse_adverse_reactions(drug_name="apixaban")
-> Bleeding rates and other AEs from label1. FDAGSRS_search_substances(query="apixaban")
-> UNII、物质类别、ATC/DrugBank交叉引用
2. RxClass_get_drug_classes(drug_name="apixaban", rela_source="ATC")
-> ATC代码B01AF02(直接因子Xa抑制剂)
3. FDA_OrangeBook_search_drug(brand_name="ELIQUIS")
-> NDA206518、批准日期、TE代码
4. FDA_OrangeBook_check_generic_availability(brand_name="ELIQUIS")
-> 仿制药可用性状态
5. FDA_OrangeBook_get_exclusivity(brand_name="ELIQUIS")
-> 独占性代码及到期日期
6. DailyMed_parse_adverse_reactions(drug_name="apixaban")
-> 标签中的出血发生率及其他不良反应Workflow 2: List All Drugs in a Therapeutic Class
工作流2:列出某治疗类别下的所有药品
1. RxClass_find_classes(query="ACE inhibitor", class_type="EPC")
-> class_id for "Angiotensin-Converting Enzyme Inhibitor"
2. RxClass_get_class_members(class_id=<id>, ttys="IN")
-> All ACE inhibitors (enalapril, lisinopril, ramipril, etc.)
3. For each drug: RxClass_get_drug_classes(drug_name=drug)
-> Confirm ATC code and additional classifications1. RxClass_find_classes(query="ACE inhibitor", class_type="EPC")
-> "血管紧张素转换酶抑制剂"的class_id
2. RxClass_get_class_members(class_id=<id>, ttys="IN")
-> 所有ACE抑制剂(依那普利、赖诺普利、雷米普利等)
3. 对每个药品:RxClass_get_drug_classes(drug_name=drug)
-> 确认ATC代码及其他分类Workflow 3: Drug Label Review
工作流3:药品标签审核
1. DailyMed_parse_adverse_reactions(drug_name="metformin")
-> AE frequencies (GI: lactic acidosis, nausea, diarrhea)
2. DailyMed_parse_contraindications(drug_name="metformin")
-> eGFR thresholds, renal impairment contraindications
3. DailyMed_parse_drug_interactions(drug_name="metformin")
-> Iodinated contrast, carbonic anhydrase inhibitor interactions
4. DailyMed_parse_clinical_pharmacology(drug_name="metformin")
-> Half-life, renal clearance, bioavailability1. DailyMed_parse_adverse_reactions(drug_name="metformin")
-> 不良反应发生率(胃肠道:乳酸酸中毒、恶心、腹泻)
2. DailyMed_parse_contraindications(drug_name="metformin")
-> eGFR阈值、肾功能不全禁忌症
3. DailyMed_parse_drug_interactions(drug_name="metformin")
-> 含碘造影剂、碳酸酐酶抑制剂相互作用
4. DailyMed_parse_clinical_pharmacology(drug_name="metformin")
-> 半衰期、肾清除率、生物利用度Common Mistakes
常见错误
- Orange Book must be UPPERCASE (e.g.,
brand_name)"LIPITOR" - requires UNII, not drug name — call
FDAGSRS_get_substancefirstFDAGSRS_search_substances - only works for chemical substances, not biologics
FDAGSRS_get_structure - : pass
RxClass_get_class_membersto restrict to active ingredientsttys="IN" search_clinical_trialsmust be an array:overall_status["RECRUITING"]
- 橙皮书的必须大写(如
brand_name)"LIPITOR" - 需要UNII,而非药品名称——需先调用
FDAGSRS_get_substanceFDAGSRS_search_substances - 仅适用于化学物质,不适用于生物制品
FDAGSRS_get_structure - :传入
RxClass_get_class_members以限制结果为活性成分ttys="IN" - 的
search_clinical_trials必须为数组格式:overall_status["RECRUITING"]
Reasoning Framework
推理框架
Interpretation Guidance
解读指南
Approval pathways: A 505(b)(1) NDA is a full new drug application with complete safety/efficacy data from the sponsor. A 505(b)(2) NDA relies partly on published literature or FDA findings for an already-approved drug (common for reformulations, new routes). An ANDA (Abbreviated NDA) is the generic pathway requiring only bioequivalence to the reference listed drug.
Orange Book patent and exclusivity: NCE (New Chemical Entity) exclusivity gives 5 years of data protection. ODE (Orphan Drug Exclusivity) gives 7 years. PED (Pediatric) adds 6 months to existing patents/exclusivity. A TE code of "AB" means the generic is therapeutically equivalent and substitutable. No TE code or "BX" means substitutability is not established.
DailyMed label sections: The "Adverse Reactions" section distinguishes clinical trial rates (controlled) from post-marketing reports (uncontrolled, signal-only). "Contraindications" are absolute; "Warnings and Precautions" are conditional risks. "Clinical Pharmacology" provides PK parameters (Cmax, AUC, half-life) essential for drug interaction and dosing assessment.
审批路径:505(b)(1) NDA是包含申办方提供的完整安全性/有效性数据的全新药品申请。505(b)(2) NDA部分依赖已发表文献或FDA对已批准药品的研究结果(常见于改良剂型、新给药途径)。ANDA(简化新药申请)是仿制药路径,仅需证明与参比制剂生物等效。
橙皮书专利与独占性:NCE(新化学实体)独占性提供5年数据保护。ODE(孤儿药独占性)提供7年保护。PED(儿科用药)为现有专利/独占性延长6个月。TE代码为"AB"表示仿制药具有治疗等效性,可替代。无TE代码或代码为"BX"表示可替代性未确立。
DailyMed标签章节:“不良反应”章节区分临床试验中的发生率(受控)与上市后报告(非受控,仅为信号)。“禁忌症”为绝对禁忌;“警告与注意事项”为条件性风险。“临床药理学”提供药代动力学参数(Cmax、AUC、半衰期),对药物相互作用和给药方案评估至关重要。
Synthesis Questions
综合问题
A complete drug regulatory report should answer:
- What is the current FDA approval status and pathway (NDA vs ANDA vs 505(b)(2))?
- Are generic equivalents available, and what is their therapeutic equivalence rating?
- When do key patents and exclusivities expire (or have they already)?
- What drug class does this belong to (ATC, EPC, MoA), and what are peer drugs in the class?
- What are the most clinically significant adverse reactions and contraindications from the label?
一份完整的药品监管报告应回答:
- 当前FDA批准状态及路径(NDA vs ANDA vs 505(b)(2))是什么?
- 是否有等效仿制药,其治疗等效性评级如何?
- 关键专利与独占性何时到期(或是否已到期)?
- 该药品属于哪类(ATC、EPC、MoA),同类竞品有哪些?
- 标签中最具临床意义的不良反应和禁忌症是什么?